Geron Corporation (GERN)
GERN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.20
-1.64% on the day
Market cap
$771.0M
Small cap
Revenue · 2023
$237K
No prior year to compare
Net income · 2023
-$184.1M
-77690.7% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2023.
Profile
| Field | Value |
|---|---|
| Ticker | GERN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1996 |
| SEC CIK | 0000886744 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $237K |
| Net income | -$184.1M |
| Operating income | -$193.9M |
| Net margin | -77690.7% |
| Operating margin | -81832.9% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $70.0M |
| Total assets | $394.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3253.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-03-02 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy | DEFA14A | 2026-04-07 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.8% |
| 1 month | -9.2% |
| 3 months | -16.2% |
| Year to date | -9.8% |
| 1 year | -6.3% |
| From 52-week high | -39.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HELP | Helus Pharma Inc. | $10.50 | -4.80% | $767.1M |
| ARDX | Ardelyx Inc. | $3.12 | -3.41% | $777.5M |
| ANL | Adlai Nortye Group Ltd. | $11.76 | -17.34% | $757.0M |
| CRVS | Corvus Pharmaceuticals Inc. | $9.41 | -6.37% | $791.6M |
| AVBP | ArriVent BioPharma Inc. | $16.09 | -2.25% | $793.4M |
| GYRE | Gyre Therapeutics Inc. | $6.71 | -2.26% | $748.2M |
| APMD | Apnimed Inc. | $17.83 | -4.29% | $742.3M |
| OBX | Obsidian Therapeutics Inc. | $11.99 | -6.25% | $740.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier